Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 17 January 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the European Patent Office has granted ... read more

Uppsala, Sweden – January 11, 2019 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis’s gene... read more

STOCKHOLM, SWEDEN – 07 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has completed patient enrollment in its Multi-Centre, Phase II, Randomized, Double-Blind, Pla... read more

BOSTON and STOCKHOLM, Jan. 7, 2019 /PRNewswire/ -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief Executive Officer, is ... read more

Uppsala, Sweden – January 7, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo’s novel naloxone nasal sp... read more